CAT #: AML-MRD-MFC

AML MRD Assay Multiparametric Flow Cytometry

  • Description of Test:

    Measurable residual disease, also called “minimal residual disease” (MRD) refers to persistent leukemic cells in the blood or bone marrow of cancer patients during or after treatment. Undetected or untreated MRD is a main cause of cancer recurrence hence sensitive MRD tests are necessary for guiding optimal treatment programs and providing a prognostic indicator for risk stratification of treated patients.

    Multiparametric Flow Cytometry (MFC) is a widely accepted platform for accessing MRD in patients with Acute Myeloid Leukemia (AML) and can be performed within a short period of time. In our lab we utilize a comprehensive panel of antibody markers to characterize potential AML blast cells using a LAIP based different from normal (DfN) approach. This approach takes into account information from diagnosis, if available but also identifies aberrant cells that have differentiated from normal maturation without previous patient history.

    Using a comprehensive selection of antibodies and a standardized panel across all testing points, MRD populations can be characterized and tracked down to 0.01%. Utilizing up to 12 biomarkers per tube allows for the identification of more LAIPS with less sample than previously was available before. 

    This panel not only provides evaluation and monitoring of patients with hematological malignancy but provides a wide array of applications due to its comprehensive biomarker selection.

  • Overview:

    Biomarkers in the AML MRD Assay

    CD2, CD4, CD5, CD7, CD11b, CD13, CD14, CD15, CD16, CD19, CD33, CD34, CD36, CD38, CD45, CD 56, CD64, CD117, CD123, HLADR, 7AAD

Service Details

Legal Notice

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶
LATEST NEWS

Invivoscribe Launches New Division for Drug Development ⟶

CONNECT